Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.1800 (0.78%) ($5.0100 - $5.1800) on Mon. Apr. 5, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.05% (three month average) | RSI | 50 | Latest Price | $5.1800(0.78%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.6% a day on average for past five trading days. | Weekly Trend | ADMS declines -4.9% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) TIP(47%) BWX(43%) EMHY(40%) IGOV(27%) EWY(21%) | Factors Impacting ADMS price | ADMS will decline at least -2.525% in a week (0% probabilities). TAN(-17%) UUP(-42%) INDA(-19%) ICLN(-16%) XLK(-14%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.525% (StdDev 5.05%) | Hourly BBV | 0.1 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $4.97(4.23%) | 10 Day Moving Average | $5.07(2.17%) | 20 Day Moving Average | $5.15(0.58%) | To recent high | -22.2% | To recent low | 3.2% | Market Cap | $146m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |